Generation of recombinant parapoxviruses: Non-essential genes suitable for insertion and expression of foreign genes

Journal of Biotechnology

Volumn 83, Issue 1-2, 2000, Pages 137-145

  Rziha, H J ^a   Henkel, M ^a   Cottone, R ^a   Bauer, B ^a   Auge, U ^b   Gotz F ^b   Pfaff, E ^a   Rottgen M ^c   Dehio, C ^c   Buttner M ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MAX PLANCK INST FÜR BIOLOGIE   (Germany)

Author keywords

Adaptation to cell line; Genomic alterations; Immune response; Orf virus D1701; Poxvirus; Recombinant parapoxvirus; vegf e gene deletion

Indexed keywords

CYTOLOGY; GENETIC ENGINEERING; LIVING SYSTEMS STUDIES; MOLECULAR STRUCTURE; VIRUSES;

PARAPOXVIRUSES; PATHOGENICITY;

VACCINES;

VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARAPOXVIRUS; PRIORITY JOURNAL; VERO CELL; VIROGENESIS; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMAL; CATTLE; CELL LINE; HUMAN; PARAPOXVIRUS; RECOMBINATION, GENETIC; SHEEP; SUPPORT, NON-U.S. GOV'T; TRANSFECTION; VIRAL PROTEINS; VIRAL VACCINES;

EID: 17744407951     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(00)00307-2     Document Type: Article

References (21)

1. Büttner M. Safety and efficacy of a combined parapox/BDV vaccine. Dev. Biol. Stand. 65:1986;221-226.
2. Büttner M. Principles of paramunization. Option and limits in veterinary medicine. Comp. Immun. Microbiol. Infect. Dis. 16:1993;1-10.
3. Brubaker J.O., Thompson C.M., Morrison L.A. et al. Th1-associated immune response to β-galactosidase expressed by a replication-defective herpes simples virus. J. Immunol. 157:1996;1598-1604.
4. Cottone R., Büttner M., Bauer B. et al. Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701. Virus Res. 56:1998;53-67.
5. Falkner F.G., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62:1988;1849-1854.
6. Fleming S.B., McCaughan C.A., Andrews A.E., Nash A.D., Mercer A.A. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J. Virol. 71:1997;4857-4861.
7. Fleming S.B., Lyttle D.J., Sullivan J.T., Mercer A.A., Robinson A.J. Genomic analysis of a transposition-deletion variant of orf virus reveals a 3,3 kbp region of non-essential DNA. J. Gen. Virol. 76:1995;2669-2978.
8. Haig D.McK., McInnes C.J., Hutchinson G., Seow H.-F., Reid H.W. Cyclosporin A abrogates the acquired immunity to cutaneous reinfection with the parapoxvirus orf. Immunology. 89:1996;524-531.
9. Haig D.M., McInnes C., Deane D., Reid H., Mercer A. The immune and inflammatory response to orf virus. Comp. Immunol. Microbiol. Infect. Dis. 20:1997;197-204.
10. Haig D.M., Mercer A.A. Ovine diseases. Orf. Vet. Res. 29:1998;311-326.
11. Hussain K.A., Burger D. In vivo and in vitro characteristics of contagious ecthyma virus isolates: Host response mechanism. Vet. Microbiol. 19:1989;23-36.
12. Lyttle D.J., Fraser K.M., Fleming S.B., Mercer A.A., Robinson A.J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68:1994;84-92.
13. Mayr A., Büttner M. Ecthyma (Orf) virus. Dinter Z., Morein B. Virus Infections of Vertebrates. 3:1990;33-42 Amsterdam, Elsevier.
14. Mayr A., Herlyn M., Mahnel H. et al. Control of contagious ecthyma in sheep by means of a new parenteral cell culture derived live vaccine. J. Med. Vet. B. 28:1981;535-549.
15. McInnes C., Wood A.R., Mercer A.A. Orf virus encodes a homolog of the vaccinia virus interferon-resistance gene E3L. Virus Genes. 17:1998;107-115.
16. Meyer M., Lanz C., Clauss M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling by VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J. 18:1999;363-374.
17. Ogawa S., Oku A., Sawano A. et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 47:1998;31273-31282.
18. Pfleiderer M., Falkner F.G., Dorner F. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts. J. Gen. Virol. 76:1995;2957-2962.
19. Robinson, A.J., Lyttle, D.J., 1992. Parapoxviruses: Their biology and potential as recombinant vaccines. In: Binns, M.M., Smith, G.L. (Eds.), Recombinant poxviruses. CRC Press Inc., Boca Raton, FL, pp. 285-327.
20. Rziha H.-J., Henkel M., Cottone R. et al. Parapoxviruses: Potential alternative vectors for directing the immune response in permissive and non-permissive hosts. J. Biotechnol. 73:1999;235-242.
21. Wise L.M., Veikkola T., Mercer A.A. et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. USA. 96:1999;3071-3076.